Following in the footsteps of his predecessor, James Ogle has left his post as a top executive at Quintiles to take the lead job at INC Research.

In addition to his role as the new chief executive officer of INC Research, Ogle will serve as a member of the company’s board of directors. INC Research is a contract research organization (CRO) specializing in central nervous system, oncology and data services.

The former CEO of INC Research, and its subsidiary DataSpectrum, was Glenn Bilawsky, who had served in that role since August 2000. Bilawsky also joined INC from Quintiles, when the CRO moved to Raleigh from San Diego.

At Quintiles, Bilawsky held positions such as executive vice president of worldwide business development and group president.

Ogle headed Quintiles Product Development Group as president and chief operating officer. Under his leadership, the group realized revenue growth and increased market share.

Prior to this, Ogle held several executive positions, including president of Quintiles Americas, president and CEO of BRI International, and president of ERC BioServices.

Ogle also has held several board positions in the pharmaceutical industry. Before beginning his professional life in the CRO industry, Ogle achieved the rank of lieutenant colonel in the U.S. Army in a 20-year military career.

“Jim Ogle is a seasoned executive who has the proven ability to successfully grow companies and drive revenue growth,” said Don Milder, chairman of INC Research. “Jim’s skills and multinational experience in this industry will take the — business into the next phase of its evolution as a specialized global partner for pharma and biotech.”

INC Research has developed a reputation in the industry based on its CNS, oncology and data services expertise, combined with its customer-dedicated focus.

“I look forward to further building the INC Research business model in the dynamic market we serve,” says Ogle. “We will grow and manage the business to maximize our distinct competitive advantages, and to continue providing our customers the most innovative solutions to manage their critical programs.”

INC Research, through its CNS and Oncology divisions, manages clinical development programs for companies developing treatments targeting central nervous system disorders and cancer. In addition, its Pediatric and Adolescent Services Group offers drug development services for products to treat neonatal, pediatric and adolescent illnesses.

INC Research: